PERK activation mitigates tau pathology in vitro and in vivo-Reference-Cited by-同舟云学术

PERK activation mitigates tau pathology in vitro and in vivo

Published:2017-02 Issue:3 Volume:9 Page:371-384
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Bruch Julius¹²³,Xu Hong¹²³,Rösler Thomas W¹²,De Andrade Anderson¹³,Kuhn Peer‐Hendrik⁴⁵,Lichtenthaler Stefan F³⁴⁶,Arzberger Thomas⁷,Winklhofer Konstanze F³⁸,Müller Ulrich⁹,Höglinger Günter U¹²³^ORCID

Affiliation:

1. Department of Translational Neurodegeneration German Center for Neurodegenerative Diseases (DZNE) Munich Germany

2. Department of Neurology Technical University of Munich (TUM) Munich Germany

3. Munich Cluster for Systems Neurology (SyNergy) Munich Germany

4. Neuroproteomics, Klinikum rechts der Isar and Institute for Advanced Study Technical University of Munich (TUM) Munich Germany

5. Institute of Pathology Technical University of Munich (TUM) Munich Germany

6. Neuroproteomics German Center for Neurodegenerative Diseases (DZNE) Munich Germany

7. Center for Neuropathology and Prion Research (ZNP) University of Munich Munich Germany

8. Department of Molecular Cell Biology Institute of Biochemistry and Pathobiochemistry Ruhr University Bochum Germany

9. Institute for Human Genetics University of Giessen Giessen Germany

Funder

Bayerische Forschungsstiftung

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

NOMIS Stiftung

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201606664

Reference52 articles.

1. Tau Accumulation Activates the Unfolded Protein Response by Impairing Endoplasmic Reticulum-Associated Degradation

2. Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein

3. Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

4. Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

5. The eIF2α Kinases PERK and PKR Activate Glycogen Synthase Kinase 3 to Promote the Proteasomal Degradation of p53

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the neuroprotective potential of Nrf2-pathway activators against annonacin toxicity;Scientific Reports;2024-08-29

2. Impairment of Nrf2 signaling in the hippocampus of P301S tauopathy mice model aligns with the cognitive impairment and the associated neuroinflammation;Journal of Inflammation;2024-08-06

3. Αnti-prion effects of anthocyanins;Redox Biology;2024-06

4. Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects;Journal of Alzheimer's Disease;2024-04-02

5. Transgenic Dendra2::tau expression allows in vivo monitoring of tau proteostasis in Caenorhabditis elegans;Disease Models & Mechanisms;2024-03-01